Form 4: SERA CMO Acquires 17,437 RSUs and 27,034 Stock Options

SERA Prognostics' Chief Medical Officer, Tiffany Eul Davis Inglis, acquired 17,437 restricted stock units and 27,034 stock options on March 12, 2026.

Summary

• Tiffany Eul Davis Inglis, Chief Medical Officer of SERA Prognostics, Inc., acquired 17,437 shares of Class A Common Stock in the form of restricted stock units (RSUs) on March 12, 2026.
• The RSUs were acquired at a price of $0 per share, bringing her total direct beneficial ownership of Class A Common Stock to 92,437 shares.
• These RSUs vest over four years, with 1/16 of the original grant vesting in quarterly installments following a vesting commencement date of March 10, 2026, contingent on continued service.
• Additionally, Ms. Inglis acquired 27,034 stock options with an exercise price of $1.99 per share on March 12, 2026.
• These stock options vest over four years, with 1/48 of the original grant vesting in monthly installments following a vesting commencement date of March 10, 2026, also contingent on continued service.
• The stock options have an expiration date of March 12, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the Chief Medical Officer is increasing her equity stake, aligning her interests with long-term shareholder value and demonstrating continued commitment to the company.

Positives

• The Chief Medical Officer's acquisition of additional equity, through both restricted stock units and stock options, aligns her long-term interests with those of shareholders.
• The vesting schedules for both the RSUs and stock options incentivize the executive's continued service and commitment to the company's performance over a four-year period.

Future Outlook

The vesting schedules for the acquired restricted stock units and stock options indicate a forward-looking compensation structure designed to retain the Chief Medical Officer and align her performance with the company's long-term success over the next four years.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options to key executives is a standard practice in the biotechnology and healthcare sectors. This form of equity compensation is widely used to attract, retain, and motivate top talent, aligning executive incentives with shareholder value creation. Such grants are common across companies like Illumina, Inc. (ILMN) or Guardant Health, Inc. (GH) for their executive teams, reflecting a commitment to long-term growth and innovation.

Comparison to Industry Standards

• The four-year vesting schedule for both RSUs and stock options is consistent with typical executive equity compensation plans observed in the U.S. market, often seen in companies like Exact Sciences Corp. (EXAS) or Natera, Inc. (NTRA) for similar roles.
• The grant of equity at a $0 price for RSUs and a specific exercise price for options is standard for incentive-based compensation, reflecting common practices in the life sciences industry for aligning executive interests with company performance.

Stakeholder Impact

• Shareholders: The transaction aligns the Chief Medical Officer's financial interests with long-term shareholder value, potentially fostering greater commitment to company performance.
• Employees: The equity grant serves as an example of executive compensation, which can influence overall employee morale and perception of compensation fairness within the company.

Next Steps

• The restricted stock units will vest quarterly over four years, subject to the reporting person's continued service.
• The stock options will vest monthly over four years, subject to the reporting person's continued service.

Key Dates

Recommendation

The acquisition of restricted stock units and stock options by a key executive, while a positive sign of alignment, is a standard compensation event and does not fundamentally alter the company's financial outlook or operational performance to warrant a change from a 'hold' position. It reinforces management's long-term commitment but does not present new information that would significantly shift investment thesis.

Keywords

SERA Prognostics, SERA, Form 4, insider transaction, restricted stock units, RSU, stock options, equity compensation, Chief Medical Officer, beneficial ownership